How to make digital adoption a smooth journeyFour big pharma experts explain the challenges companies face in adopting digital tech and what trends are likely Share XHow to make digital adoption a smooth journeyhttps://pharmaphorum.com/views-analysis-sales-marketing/digital-adoption-smooth-journey/
MHRA says Avastin can be used for AMD despite Bayer, Novartis objectionsThe UK drugs regulator has endorsed the use of Roche’s Avastin as a treatment for age-related macular degeneration, Share XMHRA says Avastin can be used for AMD despite Bayer, Novartis objectionshttps://pharmaphorum.com/news/mhra-says-avastin-can-be-used-for-amd-despite-bayer-novartis-objections/
Bayer’s Vitrakvi is first tumour-agnostic drug approved in EUBayer’s TRK inhibitor Vitrakvi has been approved by the EMA, becoming the first therapy for cancer based on Share XBayer’s Vitrakvi is first tumour-agnostic drug approved in EUhttps://pharmaphorum.com/news/bayers-vitrakvi-is-first-tumour-agnostic-drug-approved-in-eu/
Novartis backs brolucizumab with new head-to-head Eylea trialNovartis is launching a head-to-head trial of its experimental brolucizumab therapy for age-related macular degeneration (AMD) against Bayer/Regeneron’s Share XNovartis backs brolucizumab with new head-to-head Eylea trialhttps://pharmaphorum.com/news/novartis-backs-brolucizumab-with-new-head-to-head-eylea-trial/
Bayer confirms sale of animal health unit to Elanco for $7.6bnThe rumoured sale of Bayer’s animal health unit to Elanco has been confirmed as going ahead, with the Share XBayer confirms sale of animal health unit to Elanco for $7.6bnhttps://pharmaphorum.com/news/bayer-confirms-sale-of-animal-health-unit-to-elanco-for-7-6bn/
FDA approves Roche’s “tumour agnostic” drug RozlytrekThe FDA has approved Roche’s Rozlytrek (entrectinib), a so-called “tumour agnostic” drug that is approved to key into certain mutations in Share XFDA approves Roche’s “tumour agnostic” drug Rozlytrekhttps://pharmaphorum.com/news/fda-approves-roches-tumour-agnostic-drug-rozlytrek/
Bayer boosts cell therapy pipeline with BlueRock acquisitionBayer has announced it is fully acquiring US cell therapy biotech BlueRock Therapeutics, whose cell therapy pipeline includes Share XBayer boosts cell therapy pipeline with BlueRock acquisitionhttps://pharmaphorum.com/news/bayer-boosts-cell-therapy-pipeline-with-bluerock-acquisition/
NICE backs Bayer’s Xarelto in new stroke and heart attack prevention useBayer’s Xarelto (rivaroxaban) can be funded by the NHS to prevent strokes and heart attacks in high-risk adults Share XNICE backs Bayer’s Xarelto in new stroke and heart attack prevention usehttps://pharmaphorum.com/news/nice-backs-bayers-xarelto-in-new-stroke-and-heart-attack-prevention-use/
Bayer aims at J&J and Pfizer with new prostate cancer drugThe FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease Share XBayer aims at J&J and Pfizer with new prostate cancer drughttps://pharmaphorum.com/news/bayer-aims-at-jj-and-pfizer-with-new-prostate-cancer-drug/
